中国防痨杂志 ›› 2026, Vol. 48 ›› Issue (7): 1051-1063.doi: 10.19982/j.issn.1000-6621.20260030
收稿日期:2026-01-16
出版日期:2026-07-10
发布日期:2026-07-02
通信作者:
李风森,Email:基金资助:
Yin Shiliu1, Xu Dan2, Li Zheng2, Wang Yanqian3, Li Fengsen3(
)
Received:2026-01-16
Online:2026-07-10
Published:2026-07-02
Contact:
Li Fengsen, Email: Supported by:摘要:
目的: 运用文献计量学方法分析结核后遗症领域的研究特征、热点主题与知识脉络,为该领域的后续深入探索提供参考。方法: 基于Web of Science核心合集数据库,检索时间范围为2006年1月1日至2025年12月1日,检索与结核后遗症相关的“article”和“review”,利用CiteSpace V6.4.R1、VOSviewer 1.6.18软件对发文特征、国家、机构、作者、期刊分布、合作网络、文献共被引,以及关键词聚类、共现、突现及时间线进行分析。结果: 2006—2025年结核后遗症研究的发文量由2006年的2篇增至2025年的42篇。发文涉及45个国家/地区和44种期刊,发文量居于前5名的国家是美国(74篇)、英国(55篇)、南非(48篇)、中国(36篇)、韩国(23篇)。高产机构前3位为开普敦大学(10篇)、斯泰伦博斯大学(9篇)及威特沃特斯兰德大学(7篇)。关键词分析显示,共纳入333个关键词,生成671条连线,网络密度为0.012。聚类图显示,Q=0.6656、S=0.8486,依次为气流受限、肺康复、抗逆转录病毒治疗、肺功能损害、慢性肺曲霉病、结核后肺疾病、慢性阻塞性肺疾病、危险因素、肺肿瘤、肺纤维化。研究热点集中于结核后肺疾病、肺功能损伤、结核后遗症流行病学特征、危险因素及社会负担,其中结核后肺疾病的突现强度始终处于较高水平。结论: 结核后遗症当前研究聚焦气流受限、结核后肺疾病、肺功能损伤等核心议题,虽有肺康复相关干预探索,但缺乏精准化方案与共识指南。未来应聚焦发病机制、精准干预与康复管理核心方向,加大研究投入与探索力度,完善多学科协作体系,以全面提升结核后遗症的防治质量与患者长期健康水平。
中图分类号:
尹石榴, 徐丹, 李争, 王岩倩, 李风森. 结核后遗症研究的文献计量学分析(2006—2025年):一项基于Web of Science的初步探索[J]. 中国防痨杂志, 2026, 48(7): 1051-1063. doi: 10.19982/j.issn.1000-6621.20260030
Yin Shiliu, Xu Dan, Li Zheng, Wang Yanqian, Li Fengsen. Bibliometric analysis of research on post-tuberculosis sequelae (2006—2025): a preliminary exploration based on Web of Science[J]. Chinese Journal of Antituberculosis, 2026, 48(7): 1051-1063. doi: 10.19982/j.issn.1000-6621.20260030
表4
结核后遗症研究领域被引频次最高的前10篇文献
| 第一作者 | 标题 | 发表期刊 | 发表年份 | 总被引频次 |
|---|---|---|---|---|
| Ravimohan[ | Tuberculosis and lung damage: f-rom epidemiology to pathophysi-ology | European Respiratory Review | 2018 | 344 |
| Romanoski[ | Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis | Lancet Global Health | 2019 | 202 |
| Allwood[ | Post-tuberculosis lung health: perspectives from the First Internatonal Symposium | International Journal of Tuberculosis and Lung Disease | 2020 | 154 |
| Allwood[ | Post-Tuberculosis Lu-ng Disease: Clinical Review of an Under-Recognised Global Challenge | Respiration | 2021 | 151 |
| Menzies[ | Lifetime burden of disease due t-o incident tuberculosis: a global reappraisal including post-tuberculosis sequelae | Lancet Global Health | 2021 | 149 |
| Meghji[ | Patient outcomes associated with post-tuberculosis lung damage in Malawi: a prospective cohort study | Thorax | 2021 | 128 |
| Migliori[ | Clinical standards f-or the assessment, management and rehabilitation of post-TB lung disease | International Journal of Tuberculosis and Lung Disease | 2021 | 127 |
| Dodd[ | Quantifying the global number of tuberculosis survivors: a modelling study | The Lancet Infectious Diseases | 2021 | 100 |
| Van Kampen[ | International research and guidelines on post-tuberculosis chronic lung disorders: a systematic sco-ping review | BMJ Global Health | 2018 | 92 |
| Nightingale[ | Post-TB health and wellbeing | International Journal of Tuberculosis and Lung Disease | 2023 | 79 |
| [1] | 屈燕, 李涛, 马文斌, 等. 世界卫生组织《2025年全球结核病报告》解读[J]. 结核与肺部疾病杂志, 2025, 6(6): 613-623. doi:10.19983/j.issn.2096-8493.20250178. |
| [2] |
Allwood B W, van der Zalm M M, Amaral A F S, et al. Post-tuberculosis lung health: perspectives from the First International Symposium[J]. Int J Tuberc Lung Dis, 2020, 24(8): 820-828. doi:10.5588/ijtld.20.0067.
pmid: 32912387 |
| [3] |
Allwood B W, Nightingale R, Agbota G, et al. Perspectives from the 2nd International Post-Tuberculosis Symposium: mobilising advocacy and research for improved outcomes[J]. IJTLD Open, 2024, 1(3): 111-123. doi:10.5588/ijtldopen.23.0619.
pmid: 38966406 |
| [4] | Ravimohan S, Kornfeld H, Weissman D, et al. Tuberculosis and lung damage: from epidemiology to pathophysiology[J]. Eur Respir Rev, 2018, 27(147): 170077. doi:10.1183/16000617.0077-2017. |
| [5] |
Meghji J, Lesosky M, Joekes E, et al. Patient outcomes associated with post-tuberculosis lung damage in Malawi: a prospective cohort study[J]. Thorax, 2020, 75(3): 269-278. doi:10.1136/thoraxjnl-2019-213808.
pmid: 32102951 |
| [6] | Xing Z, Sun T, Janssens J P, et al. Airflow obstruction and small airway dysfunction following pulmonary tuberculosis: a cross-sectional survey[J]. Thorax, 2023, 78(3): 274-280. doi:10.1136/thoraxjnl-2021-218345. |
| [7] | Woldesemayat E M, Vera J H, Tanner C, et al. Lung function of tuberculosis patients after completion of treatment in Sidama, South Ethiopia[J]. Front Med (Lausanne), 2025, 12: 1451861. doi:10.3389/fmed.2025.1451861. |
| [8] | Basham C A, Karim M E, Cook V J, et al. Post-tuberculosis airway disease: A population-based cohort study of people immigrating to British Columbia, Canada, 1985—2015[J]. EClinicalMedicine, 2021, 33: 100752. doi:10.1016/j.eclinm.2021.100752. |
| [9] |
Chin A T, Rylance J, Makumbirofa S, et al. Chronic lung disease in adult recurrent tuberculosis survivors in Zimbabwe: a cohort study[J]. Int J Tuberc Lung Dis, 2019, 23(2): 203-211. doi:10.5588/ijtld.18.0313.
pmid: 30808453 |
| [10] | Gai X, Allwood B, Sun Y. Post-tuberculosis lung disease and chronic obstructive pulmonary disease[J]. Chin Med J (Engl), 2023, 136(16): 1923-1928. doi:10.1097/CM9.0000000000002771. |
| [11] | Joo D H, Kim M C, Sin S, et al. Incidence and Risk Factors of Tuberculosis-Associated Chronic Obstructive Pulmonary Disease[J]. Int J Chron Obstruct Pulmon Dis, 2025, 20: 2091-2102. doi:10.2147/COPD.S523732. |
| [12] | Choi H, Lee H, Ra S W, et al. Clinical Characteristics of Patients with Post-Tuberculosis Bronchiectasis: Findings from the KMBARC Registry[J]. J Clin Med, 2021, 10(19): 4542. doi:10.3390/jcm10194542. |
| [13] | Raj P A, Leach L A D, Davis C E. Chronic Lung Damage After Tuberculosis: A Focus on Bronchiectasis and Its Management[J]. Am J Respir Crit Care Med, 2025, 211: A2049. doi:10.1164/ajrccm.2025.211.Abstracts.A2409. |
| [14] |
Liu T, Gao L, Xie S, et al. Clinical and imaging spectrum of tuberculosis-associated fibrosing mediastinitis[J]. Clin Respir J, 2018, 12(5): 1974-1980. doi:10.1111/crj.12766.
pmid: 29356415 |
| [15] | Louw E H, van Heerden J A, Kalla I S, et al. Scoping review of post-TB pulmonary vascular disease: Proceedings from the 2nd International Post-Tuberculosis Symposium[J]. Pulm Circ, 2024, 14(3): e12424. doi:10.1002/pul2.12424. |
| [16] | Louw E, Baines N, Maarman G, et al. The prevalence of pulmonary hypertension after successful tuberculosis treatment in a community sample of adult patients[J]. Pulm Circ, 2023, 13(1): e12184. doi:10.1002/pul2.12184. |
| [17] | Hanalla M, Mohamed M A, Virnig S, et al. Post-tuberculosis Destroyed Lung Syndrome: A Case Report and Review of Management Challenges[J]. Am J Respir Crit Care Med, 2025, 211: A2376. doi:10.1164/ajrccm.2025.211.Abstracts.A2376. |
| [18] | Wu C Y, Hu H Y, Pu C Y, et al. Pulmonary tuberculosis increases the risk of lung cancer: a population-based cohort study[J]. Cancer, 2011, 117(3): 618-24. doi:10.1002/cncr.25616. |
| [19] |
Simonsen D F, Farkas D K, Søgaard M, et al. Tuberculosis and risk of cancer: a Danish nationwide cohort study[J]. Int J Tuberc Lung Dis, 2014, 18(10): 1211-1219. doi:10.5588/ijtld.14.0161.
pmid: 25216835 |
| [20] | Wu M, Yang Y N, Wang F, et al. Development of a Predictive Risk Model for Recurrence of Chronic Pulmonary Aspergillosis in Post-Tuberculosis Patients: A Retrospective Observational Study[J]. Int J Gen Med, 2025, 18: 7243-7254. doi:10.2147/IJGM.S544265. |
| [21] | Soundappan K, Singh Sehgal I, Prabhakar N, et al. Incidence and prevalence of chronic pulmonary aspergillosis in patients with post-tuberculosis lung abnormality: Results from a community survey in North India[J]. Mycoses, 2024, 67(3): e13711. doi:10.1111/myc.13711. |
| [22] | Rozaliyani A, Setianingrum F, Isbaniah F, et al. A Silent Threat in Post-Tuberculosis Patients: Chronic Pulmonary Aspergillosis Survey in Multiple Regions of Indonesia (I-CHROME Study)[J]. J Fungi (Basel), 2025, 11(5): 329. doi:10.3390/jof11050329. |
| [23] | Purwono A, Fachrucha F, Agustin H, et al. Chronic Pulmonary Aspergillosis in Patient With Post-Tuberculosis Treatment and Recurrent Hemoptysis[J]. Am J Respir Crit Care Med, 2023, 207: A5571. |
| [24] | Yang J, Kim S H, Sim J K, et al. Tuberculosis survivors and the risk of cardiovascular disease: analysis using a nationwide survey in Korea[J]. Front Cardiovasc Med, 2024, 11: 1364337. doi:10.3389/fcvm.2024.1364337. |
| [25] | Mendoza-Torres J, Durán-Hernández N, Choreño-Parra J, et al. Hippocampal syndrome secondary to tuberculosis: From neuroinflammation to neurodegeneration[J]. Tuberculosis (Edinb), 2025, 153: 102653. doi:10.1016/j.tube.2025.102653. |
| [26] | Lo H Y, Suo J, Chang H J, et al. Risk factors associated with death in a 12-month cohort analysis of tuberculosis patients: 12-month follow-up after registration[J]. Asia Pac J Public Health, 2015, 27(2): NP758-68. doi:10.1177/1010539511429591. |
| [27] | Kim S, Pelissari D M, Harada L O, et al. Long-term Mortality Trends Among Individuals With Tuberculosis: A Retrospective Cohort Study of Individuals Diagnosed With Tuberculosis in Brazil[J]. Clin Infect Dis, 2026, 82(1): e1-e8. doi:10.1093/cid/ciaf206. |
| [28] | 秦丽莉, 杨澄清, 麦洪珍, 等. 结核后肺曲霉病的临床诊疗研究进展[J]. 中国防痨杂志, 2025, 47(4): 498-504. doi:10.19982/j.issn.1000-6621.20240527. |
| [29] | 宋菲尔, 毛燕君, 夏秋月, 等. 结核后肺疾病患者患病率和影响因素的Meta分析[J]. 中国防痨杂志, 2025, 47(3): 322-330. doi:10.19982/j.issn.1000-6621.20240454. |
| [30] |
Romanowski K, Baumann B, Basham C A, et al. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis[J]. Lancet Infect Dis, 2019, 19(10): 1129-1137. doi:10.1016/S1473-3099(19)30309-3.
pmid: 31324519 |
| [31] | Allwood BW, Byrne A, Meghji J, et al. Post-Tuberculosis Lung Disease: Clinical Review of an Under-Recognised Global Challenge[J]. Respiration, 2021, 100(8): 751-763. doi:10.1159/000512531. |
| [32] |
Menzies N A, Quaife M, Allwood B W, et al. Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae[J]. Lancet Glob Health, 2021, 9(12): e1679-e1687. doi:10.1016/S2214-109X(21)00367-3.
pmid: 34798027 |
| [33] |
Migliori G B, Marx F M, Ambrosino N, et al. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease[J]. Int J Tuberc Lung Dis, 2021, 25(10): 797-813. doi:10.5588/ijtld.21.0425.
pmid: 34615577 |
| [34] |
Dodd P J, Yuen C M, Jayasooriya S M, et al. Quantifying the global number of tuberculosis survivors: a modelling study[J]. Lancet Infect Dis, 2021, 21(7): 984-992. doi:10.1016/S1473-3099(20)30919-1.
pmid: 33640076 |
| [35] | van Kampen S C, Wanner A, Edwards M, et al. International research and guidelines on post-tuberculosis chronic lung disorders: a systematic scoping review[J]. BMJ Glob Health, 2018, 3(4): e000745. doi:10.1136/bmjgh-2018-000745. |
| [36] |
Nightingale R, Carlin F, Meghji J, et al. Post-TB health and wellbeing[J]. Int J Tuberc Lung Dis, 2023, 27(4): 248-283. doi:10.5588/ijtld.22.0514.
pmid: 37035971 |
| [37] |
Mpagama S G, Msaji K S, Kaswaga O, et al. The burden and determinants of post-TB lung disease[J]. Int J Tuberc Lung Dis, 2021, 25(10): 846-853. doi:10.5588/ijtld.21.0278.
pmid: 34615582 |
| [38] |
Thomson H, Baines N, Huisamen T, et al. A new understanding of clinical patterns in post-TB lung disease[J]. Int J Tuberc Lung Dis, 2024, 28(3): 115-121. doi:10.5588/ijtld.23.0327.
pmid: 38454184 |
| [39] | Webber T, Macdonald C, Tameris M, et al. Immune, metabolic, anatomical, and functional features of people after successful tuberculosis treatment: an exploratory analysis[J]. Sci Rep, 2025, 15(1): 18392. doi:10.1038/s41598-025-01656-1. |
| [40] | Wang L L, Lu H W, Li L L, et al. Destroyed lung contributes to the recurrence of hemoptysis after bronchial artery embolization in patients with post-tuberculosis bronchiectasis[J]. J Infect Public Health, 2024, 17(7): 102446. doi:10.1016/j.jiph.2024.05.003. |
| [41] | Auld S C, Barczak A K, Bishai W, et al. Pathogenesis of Post-Tuberculosis Lung Disease: Defining Knowledge Gaps and Research Priorities at the Second International Post-Tuberculosis Symposium[J]. Am J Respir Crit Care Med, 2024, 210(8): 979-993. doi:10.1164/rccm.202402-0374SO. |
| [42] | Santos A P, Rodrigues L S, Rother N, et al. The role of neutrophil response in lung damage and post-tuberculosis lung disease: a translational narrative review[J]. Front Immunol, 2025, 16: 1528074. doi:10.3389/fimmu.2025.1528074. |
| [1] | 魏黛珏, 邓明坤, 陈彦, 杨增伟, 同重湘. 血清γ-干扰素、白细胞介素2和白细胞介素6水平在60岁及以上老年肺结核患者中的表达及其临床价值[J]. 中国防痨杂志, 2026, 48(8): 1170-1175. |
| [2] | 郭晓雯, 焦天宇, 孙丽, 倪聪慧, 王梓霖, 王昊. 基于CE-T1WI影像组学的机器学习模型鉴别结核性与布鲁氏菌性脊柱炎的多中心研究[J]. 中国防痨杂志, 2026, 48(8): 1184-1191. |
| [3] | 吕永芸, 李晓琴, 吴孟泰, 周敏, 田楠, 沈凌. 疾病诊断相关分组付费模式下肺结核住院费用及影响因素研究[J]. 中国防痨杂志, 2026, 48(8): 1205-1213. |
| [4] | 杨粤琦, 傅麟淋, 何兰芳, 曹远琳, 虞斯涵, 张潆方, 夏同霞. 脊柱结核患者就医延迟影响因素及管理策略研究进展[J]. 中国防痨杂志, 2026, 48(8): 1226-1230. |
| [5] | 孙丹雨辰, 刘宇红. 利福平耐药/耐多药结核病药物治疗的卫生经济学研究进展与展望[J]. 中国防痨杂志, 2026, 48(8): 1231-1230. |
| [6] | 胡纯, 高建娣, 黄国兰, 奚璐, 伍晓青. 重症肺结核合并胸壁窦道患儿的护理实践一例[J]. 中国防痨杂志, 2026, 48(8): 1241-1244. |
| [7] | 高谦. 结核病非痰筛查的理性回归:舌拭子的固有局限与定位再思考[J]. 中国防痨杂志, 2026, 48(8): 1120-1123. |
| [8] | 廖文平, 张理翌, 吕娟, 辛玉, 苏倩, 张文. 结核菌素皮肤试验反应程度与高中学生肺结核发病风险的关联[J]. 中国防痨杂志, 2026, 48(8): 1124-1129. |
| [9] | 刘自森, 赵雅琪, 张彬, 辛赫男, 杜江, 冯博轩, 何翼君, 李子涵, 于怡麟, 王大宽, 闫娇霞, 高磊, 金奇, 段伟焘, 曹雪芳. 基于2017年结核分枝杆菌潜伏感染筛查的河南省中牟县乡村医生2025年再筛查情况及感染状态变化相关影响因素分析[J]. 中国防痨杂志, 2026, 48(8): 1139-1147. |
| [10] | 李信达, 侯志丽, 欧阳兵, 杜亚东, 关丽英, 于红梅, 张海芹, 谢勇杰, 唐佩军, 肖雨, 张瑛, 陆宇. 抗结核固定剂量复合剂治疗药物敏感肺结核的安全性和有效性[J]. 中国防痨杂志, 2026, 48(8): 1158-1162. |
| [11] | 齐云峰, 王雪钰, 康万里, 聂文娟, 王一文. 舌拭子核酸检测在疑似肺结核诊断中的应用价值[J]. 中国防痨杂志, 2026, 48(8): 1163-1169. |
| [12] | 曾李娜, 李文思, 卢海林, 汪文斐, 陈心春, 邓国防, 谢水祥. 结核分枝杆菌调控宿主脂质代谢重编程的研究进展[J]. 中国防痨杂志, 2026, 48(8): 1214-1219. |
| [13] | 中国防痨协会标准化专业分会, 中国防痨协会感染控制专业分会, 《中国防痨杂志》编辑委员会. 结核菌素皮肤试验应用指南[J]. 中国防痨杂志, 2026, 48(8): 1083-1095. |
| [14] | 王小敏, 徐鹏, 陈珍妍, 龙玉娇, 王瑾, 刘晗, 高文英, 方木通. 《结核病母婴传播防治指南》解读[J]. 中国防痨杂志, 2026, 48(8): 1113-1119. |
| [15] | 郭金龙, 闵旭红, 宋彪, 李源, 王尚虎, 陈武. 体-肺分流下肺结核患者假性肺栓塞双期计算机断层扫描血管造影的影像特征分析[J]. 中国防痨杂志, 2026, 48(8): 1192-1198. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
京公网安备11010202007215号
ip访问总数: ip当日访问总数: 当前在线人数:
本作品遵循Creative Commons Attribution 3.0 License授权许可